JP2023546298A - 多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド - Google Patents

多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド Download PDF

Info

Publication number
JP2023546298A
JP2023546298A JP2023548543A JP2023548543A JP2023546298A JP 2023546298 A JP2023546298 A JP 2023546298A JP 2023548543 A JP2023548543 A JP 2023548543A JP 2023548543 A JP2023548543 A JP 2023548543A JP 2023546298 A JP2023546298 A JP 2023546298A
Authority
JP
Japan
Prior art keywords
polypeptide
fusion
cells
fusion polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546298A5 (https=
Inventor
ディアス， クローディア アニャ ピュナフェルト
Original Assignee
キュラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラ セラピューティクス， インコーポレイテッド filed Critical キュラ セラピューティクス， インコーポレイテッド
Priority claimed from PCT/US2021/055646 external-priority patent/WO2022086988A1/en
Publication of JP2023546298A publication Critical patent/JP2023546298A/ja
Publication of JP2023546298A5 publication Critical patent/JP2023546298A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023548543A 2020-10-20 2021-10-19 多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド Pending JP2023546298A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094277P 2020-10-20 2020-10-20
US63/094,277 2020-10-20
PCT/US2021/055646 WO2022086988A1 (en) 2020-10-20 2021-10-19 Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides

Publications (2)

Publication Number Publication Date
JP2023546298A true JP2023546298A (ja) 2023-11-01
JP2023546298A5 JP2023546298A5 (https=) 2024-10-28

Family

ID=81257992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548543A Pending JP2023546298A (ja) 2020-10-20 2021-10-19 多機能性及び多価インターロイキン－ｔｇｆ－ベータ受容体融合ポリペプチド

Country Status (8)

Country Link
US (2) US11407814B2 (https=)
EP (1) EP4232466A4 (https=)
JP (1) JP2023546298A (https=)
KR (1) KR20230117341A (https=)
CN (1) CN116615441A (https=)
AU (1) AU2021367306A1 (https=)
CA (1) CA3198822A1 (https=)
IL (1) IL302269A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
US20200002425A1 (en) * 2018-03-26 2020-01-02 Altor Bioscience Corporation Anti-pdl1, il-15 and tgf-beta receptor combination molecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
US20210061871A1 (en) 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
KR102402276B1 (ko) 2019-11-15 2022-05-26 주식회사 제넥신 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
TW202233661A (zh) 2020-10-20 2022-09-01 美商克拉治療股份有限公司 多功能及多價介白素-TGF-β受體融合多肽
KR20230117341A (ko) 2020-10-20 2023-08-08 큐라 테라퓨틱스, 인크. 다기능성 및 다가 인터류킨-tgf-베타 수용체 융합 폴리펩티드
CN117120075A (zh) * 2021-02-17 2023-11-24 库拉治疗股份有限公司 抗病原体白细胞介素-TGF-β受体融合多肽

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152610A1 (en) * 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
US20200002425A1 (en) * 2018-03-26 2020-01-02 Altor Bioscience Corporation Anti-pdl1, il-15 and tgf-beta receptor combination molecules

Also Published As

Publication number Publication date
AU2021367306A1 (en) 2023-06-01
CA3198822A1 (en) 2022-04-28
EP4232466A4 (en) 2024-11-06
KR20230117341A (ko) 2023-08-08
EP4232466A1 (en) 2023-08-30
AU2021367306A9 (en) 2024-10-10
US12258383B2 (en) 2025-03-25
US20230023954A1 (en) 2023-01-26
IL302269A (en) 2023-06-01
US11407814B2 (en) 2022-08-09
CN116615441A (zh) 2023-08-18
US20220127332A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
Puca et al. The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors
KR102539359B1 (ko) 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
AU2026201764A1 (en) Oncolytic virus therapy
AU2009270434B2 (en) Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
JP2021513570A (ja) サイトカインをコードするｒｎａを用いた治療
WO2007067683A2 (en) Methods and compositions for expanding t regulatory cells
JP2024029176A (ja) 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
JP2026010064A (ja) 癌ワクチン
JP2015506961A (ja) Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用
JP2020503252A (ja) Ｔ細胞応答を促進するための方法
JP2021535083A (ja) Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
WO2019184886A1 (zh) 促进免疫细胞增殖的方法
US12258383B2 (en) Multi-functional and multi-valent interleukin-TGF-beta receptor fusion polypeptides
Klein et al. Engineering a safe monoclonal anti‐human IL‐2 that is effective in a murine model of food allergy and asthma
US12329803B2 (en) Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide
WO2022086988A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
JP2008500812A (ja) 免疫抑制サイトカイン
Croce et al. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen
Lai et al. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
CN110564749A (zh) 靶向egfr的嵌合抗原受体及其用途
WO2020146773A1 (en) Methods of using il-2/cd25 fusion protein
Mansurov Exploiting Tumor-Intrinsic Cues to Engineer Interleukin-12 for Cancer Immunotherapy
CN121693512A (zh) 包括用于治疗癌症的工程化il-7多肽和工程化il-12多肽的方法和组合物
Terando et al. Enhancing dendritic cell-based vaccines by gene modification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A603 Late request for extension of time limit during examination

Free format text: JAPANESE INTERMEDIATE CODE: A603

Effective date: 20260120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260326